Home › Companies › NEUROCRINE BIOSCIENCES INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and NEUROCRINE BIOSCIENCES INC.’s Form 8-K, filed May 23, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 22, 2024: 6 items on NEUROCRINE BIOSCIENCES INC.’s Form 8-K, filed May 23, 2024: 4 elected · 2 approved.
Notable dissent: 2 directors (15.5%, 10.2% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore NEUROCRINE BIOSCIENCES INC. in the interactive database Compare manager voting policies
These tallies are NEUROCRINE BIOSCIENCES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 23, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: William H. Rastetter, Ph.D. | 72,381,261 | -- | -- | 13,283,948 | 4,500,898 | 84% | Elected | — |
| Elect Director: George J. Morrow | 80,403,845 | -- | -- | 5,261,364 | 4,500,898 | 94% | Elected | — |
| Elect Director: Leslie V. Norwalk | 76,902,461 | -- | -- | 8,762,748 | 4,500,898 | 90% | Elected | — |
| Elect Director: Christine A. Poon | 80,898,676 | -- | -- | 4,766,533 | 4,500,898 | 94% | Elected | — |
| The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis. • Approval of the Amended 2020 Plan. | 76,076,416 | 9,499,523 | 89,270 | -- | 4,500,898 | 89% | Approved | — |
| The Amended 2020 Plan was approved. • Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. | 84,641,389 | 5,451,051 | 73,667 | -- | -- | 94% | Approved | — |
Source: NEUROCRINE BIOSCIENCES INC., Form 8-K, filed with the SEC on May 23, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
567 asset managers disclosed a vote on at least one NEUROCRINE BIOSCIENCES INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of NEUROCRINE BIOSCIENCES INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 7 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Christine A. Poon
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: Christine A. Poon”): 80,898,676 for, 4,766,533 withheld, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The four nominees for Class I Director were elected.”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 141 asset managers below reported 35,452,486 for, 1,287,740 withheld, 5,707 abstained, 7,000 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,411,577 | 0 | 0 | 0 | For |
| BlackRock | 7,425,373 | 0 | 0 | 0 | For |
| Fidelity | 1,805,276 | 0 | 0 | 0 | For |
| JPMorgan | 1,459,155 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,349,219 | 0 | 0 | 0 | For |
| State Street | 2,261 | 0 | 0 | 1,203,971 | Withhold |
| Dodge & Cox | 930,411 | 0 | 0 | 0 | For |
| Invesco | 871,521 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 800,201 | 0 | 0 | 0 | For |
| Charles Schwab | 716,462 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 625,696 | 0 | 0 | 0 | For |
| First Trust | 529,193 | 0 | 0 | 0 | For |
| Hartford | 508,568 | 0 | 0 | 0 | For |
| Jackson National | 433,968 | 0 | 0 | 0 | For |
| Lord Abbett | 376,417 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 370,830 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 356,723 | 0 | 0 | 0 | For |
| Prudential/PGIM | 347,792 | 0 | 0 | 0 | For |
| TIAA | 340,311 | 0 | 0 | 0 | For |
| Eaton Vance | 320,948 | 0 | 0 | 0 | For |
| Goldman Sachs | 305,967 | 0 | 0 | 0 | For |
| Allspring | 300,550 | 0 | 0 | 0 | For |
| John Hancock | 277,524 | 0 | 0 | 0 | For |
| Principal | 227,704 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 221,954 | 0 | 0 | 0 | For |
Showing the 25 largest of 141 asset managers. All 141 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: George J. Morrow
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: George J. Morrow”): 80,403,845 for, 5,261,364 withheld, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The four nominees for Class I Director were elected.”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 141 asset managers below reported 34,900,437 for, 1,810,860 withheld, 34,636 abstained, 7,000 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,411,577 | 0 | 0 | 0 | For |
| BlackRock | 7,425,373 | 0 | 0 | 0 | For |
| Fidelity | 1,805,276 | 0 | 0 | 0 | For |
| JPMorgan | 1,459,155 | 0 | 0 | 0 | For |
| T. Rowe Price | 76,767 | 0 | 0 | 1,272,452 | Mixed |
| State Street | 1,206,232 | 0 | 0 | 0 | For |
| Dodge & Cox | 930,411 | 0 | 0 | 0 | For |
| Invesco | 871,521 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 800,201 | 0 | 0 | 0 | For |
| Charles Schwab | 716,462 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 625,696 | 0 | 0 | 0 | For |
| First Trust | 529,193 | 0 | 0 | 0 | For |
| Hartford | 508,568 | 0 | 0 | 0 | For |
| Jackson National | 433,968 | 0 | 0 | 0 | For |
| Lord Abbett | 376,417 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 370,830 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 356,723 | 0 | 0 | 0 | For |
| Prudential/PGIM | 327,859 | 0 | 0 | 19,933 | Mixed |
| TIAA | 340,311 | 0 | 0 | 0 | For |
| Eaton Vance | 320,948 | 0 | 0 | 0 | For |
| Goldman Sachs | 54,858 | 0 | 0 | 251,109 | Mixed |
| Allspring | 300,550 | 0 | 0 | 0 | For |
| John Hancock | 249,326 | 0 | 28,198 | 0 | Mixed |
| Principal | 227,704 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 221,954 | 0 | 0 | 0 | For |
Showing the 25 largest of 141 asset managers. All 141 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Leslie V. Norwalk
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: Leslie V. Norwalk”): 76,902,461 for, 8,762,748 withheld, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The four nominees for Class I Director were elected.”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 141 asset managers below reported 33,308,901 for, 3,193,414 withheld, 250,618 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,411,577 | 0 | 0 | 0 | For |
| BlackRock | 7,425,373 | 0 | 0 | 0 | For |
| Fidelity | 1,805,276 | 0 | 0 | 0 | For |
| JPMorgan | 1,459,155 | 0 | 0 | 0 | For |
| T. Rowe Price | 76,767 | 0 | 0 | 1,272,452 | Mixed |
| State Street | 1,206,232 | 0 | 0 | 0 | For |
| Dodge & Cox | 930,411 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 871,521 | Withhold |
| JANUS INVESTMENT FUND | 800,201 | 0 | 0 | 0 | For |
| Charles Schwab | 716,462 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 625,696 | 0 | 0 | 0 | For |
| First Trust | 529,193 | 0 | 0 | 0 | For |
| Hartford | 508,568 | 0 | 0 | 0 | For |
| Jackson National | 224,473 | 0 | 209,495 | 0 | Mixed |
| Lord Abbett | 376,417 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 370,830 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 356,723 | 0 | 0 | 0 | For |
| Prudential/PGIM | 327,859 | 0 | 0 | 19,933 | Mixed |
| TIAA | 0 | 0 | 0 | 340,311 | Withhold |
| Eaton Vance | 320,948 | 0 | 0 | 0 | For |
| Goldman Sachs | 54,858 | 0 | 0 | 251,109 | Mixed |
| Allspring | 300,550 | 0 | 0 | 0 | For |
| John Hancock | 249,326 | 0 | 28,198 | 0 | Mixed |
| Principal | 227,704 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 221,954 | 0 | 0 | 0 | For |
Showing the 25 largest of 141 asset managers. All 141 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
84% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: William H. Rastetter, Ph.D.
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: William H. Rastetter, Ph.D.”): 72,381,261 for, 13,283,948 withheld, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The four nominees for Class I Director were elected.”
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 141 asset managers below reported 32,818,406 for, 3,742,990 withheld, 191,537 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,411,577 | 0 | 0 | 0 | For |
| BlackRock | 7,425,373 | 0 | 0 | 0 | For |
| Fidelity | 1,805,276 | 0 | 0 | 0 | For |
| JPMorgan | 1,459,155 | 0 | 0 | 0 | For |
| T. Rowe Price | 76,767 | 0 | 0 | 1,272,452 | Mixed |
| State Street | 2,094 | 0 | 0 | 1,204,138 | Withhold |
| Dodge & Cox | 930,411 | 0 | 0 | 0 | For |
| Invesco | 871,521 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 800,201 | 0 | 0 | 0 | For |
| Charles Schwab | 716,462 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 625,696 | 0 | 0 | 0 | For |
| First Trust | 529,193 | 0 | 0 | 0 | For |
| Hartford | 0 | 0 | 0 | 508,568 | Withhold |
| Jackson National | 433,968 | 0 | 0 | 0 | For |
| Lord Abbett | 376,417 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 370,830 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 356,723 | 0 | 0 | 0 | For |
| Prudential/PGIM | 327,859 | 0 | 0 | 19,933 | Mixed |
| TIAA | 340,311 | 0 | 0 | 0 | For |
| Eaton Vance | 320,948 | 0 | 0 | 0 | For |
| Goldman Sachs | 305,967 | 0 | 0 | 0 | For |
| Allspring | 300,550 | 0 | 0 | 0 | For |
| John Hancock | 115,879 | 0 | 161,645 | 0 | Mixed |
| Principal | 227,704 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 221,954 | 0 | 0 | 0 | For |
Showing the 25 largest of 141 asset managers. All 141 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
95% of fund votes cast · no official result
Description as filed by funds: To approve an amendment of the Company's 2020 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 3,635,000 shares; and
The 122 asset managers below reported 32,248,109 for, 1,813,928 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,138,627 | 0 | 0 | 0 | For |
| BlackRock | 7,425,373 | 0 | 0 | 0 | For |
| Fidelity | 1,576,285 | 228,991 | 0 | 0 | Mixed |
| JPMorgan | 1,459,155 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,349,219 | 0 | 0 | 0 | For |
| State Street | 2,094 | 1,204,138 | 0 | 0 | Against |
| Dodge & Cox | 930,411 | 0 | 0 | 0 | For |
| Invesco | 871,521 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 800,201 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 625,696 | 0 | 0 | 0 | For |
| First Trust | 529,193 | 0 | 0 | 0 | For |
| Jackson National | 433,968 | 0 | 0 | 0 | For |
| Lord Abbett | 376,417 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 370,830 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 356,723 | 0 | 0 | 0 | For |
| TIAA | 340,311 | 0 | 0 | 0 | For |
| Eaton Vance | 320,948 | 0 | 0 | 0 | For |
| Goldman Sachs | 305,967 | 0 | 0 | 0 | For |
| Allspring | 300,550 | 0 | 0 | 0 | For |
| John Hancock | 277,524 | 0 | 0 | 0 | For |
| Principal | 227,704 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 221,954 | 0 | 0 | 0 | For |
| Lincoln Financial | 148,552 | 34,954 | 0 | 0 | Mixed |
| Equitable | 175,187 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 172,563 | 0 | 0 | 0 | For |
Showing the 25 largest of 122 asset managers. All 122 are in the interactive database (link above).
Combines 16 wordings of this item as funds reported it.
89% Approved · of votes cast
Description as filed by funds: Advisory vote on the compensation paid to the Company's named executive officers;
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis. • Approval of the Amended 2020 Plan.”): 76,076,416 for, 9,499,523 against — passed, per its Form 8-K filed May 23, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,411,577 | 0 | 0 | 0 | For |
| BlackRock | 7,425,373 | 0 | 0 | 0 | For |
| Fidelity | 1,805,276 | 0 | 0 | 0 | For |
| JPMorgan | 1,459,155 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,272,452 | 76,767 | 0 | 0 | Mixed |
| State Street | 1,206,232 | 0 | 0 | 0 | For |
| Dodge & Cox | 930,411 | 0 | 0 | 0 | For |
| Invesco | 871,521 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 800,201 | 0 | 0 | 0 | For |
| Charles Schwab | 716,462 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 625,696 | 0 | 0 | 0 | For |
| First Trust | 529,193 | 0 | 0 | 0 | For |
| Hartford | 508,568 | 0 | 0 | 0 | For |
| Jackson National | 433,968 | 0 | 0 | 0 | For |
| Lord Abbett | 376,417 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 370,830 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 356,723 | 0 | 0 | 0 | For |
| Prudential/PGIM | 347,792 | 0 | 0 | 0 | For |
| TIAA | 340,311 | 0 | 0 | 0 | For |
| Eaton Vance | 320,948 | 0 | 0 | 0 | For |
| Goldman Sachs | 305,967 | 0 | 0 | 0 | For |
| Allspring | 300,550 | 0 | 0 | 0 | For |
| John Hancock | 277,524 | 0 | 0 | 0 | For |
| Principal | 227,704 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 221,954 | 0 | 0 | 0 | For |
Fund voting reports, all 140 managers: 36,429,690 for, 270,527 against, 49,665 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 5,295,263 | 518 | 0 | 0 | For |
| State Street | 3,614,963 | 0 | 0 | 0 | For |
| Man Group plc | 2,268,940 | 0 | 0 | 0 | For |
| JPMorgan | 1,920,859 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,661,143 | 141,694 | 0 | 0 | Mixed |
| GEODE CAPITAL MANAGEMENT, LLC | 1,675,222 | 0 | 0 | 0 | For |
| Renaissance | 1,450,218 | 0 | 0 | 0 | For |
| Janus Henderson | 1,391,296 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,162,220 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 1,055,000 | 0 | 0 | 0 | For |
| DSM CAPITAL PARTNERS LLC | 1,007,585 | 0 | 0 | 0 | For |
| Wellington | 959,016 | 0 | 0 | 0 | For |
| Invesco | 938,044 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 923,979 | 0 | 0 | 0 | For |
| BROWN ADVISORY INC | 923,751 | 0 | 0 | 0 | For |
| Point72 | 868,582 | 0 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 826,029 | 0 | 0 | 0 | For |
| Northern Trust | 810,623 | 1,976 | 0 | 0 | For |
| Polar Capital Holdings Plc | 805,556 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 781,541 | 0 | 0 | 0 | For |
| Charles Schwab | 745,803 | 0 | 0 | 0 | For |
| APG Asset Management US Inc. | 0 | 0 | 732,305 | 0 | Abstain |
| FRANKLIN ADVISERS INC | 722,144 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 721,192 | 0 | 0 | 0 | For |
| EAGLE ASSET MANAGEMENT INC | 709,799 | 0 | 0 | 0 | For |
Institutional-manager reports, all 461 managers: 54,042,411 for, 2,976,452 against, 732,305 abstained, 1,766 not voted, 19 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
94% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“The Amended 2020 Plan was approved. • Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 84,641,389 for, 5,451,051 against — passed, per its Form 8-K filed May 23, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Amended 2020 Plan was approved.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 144 asset managers below reported 36,620,229 for, 113,581 against, 49,665 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,411,577 | 0 | 0 | 0 | For |
| BlackRock | 7,425,373 | 0 | 0 | 0 | For |
| Fidelity | 1,805,276 | 0 | 0 | 0 | For |
| JPMorgan | 1,459,155 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,349,219 | 0 | 0 | 0 | For |
| State Street | 1,206,065 | 167 | 0 | 0 | For |
| Dodge & Cox | 930,411 | 0 | 0 | 0 | For |
| Invesco | 871,521 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 800,201 | 0 | 0 | 0 | For |
| Charles Schwab | 716,462 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 625,696 | 0 | 0 | 0 | For |
| First Trust | 529,193 | 0 | 0 | 0 | For |
| Hartford | 508,568 | 0 | 0 | 0 | For |
| Jackson National | 433,968 | 0 | 0 | 0 | For |
| Lord Abbett | 376,417 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 370,830 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 356,723 | 0 | 0 | 0 | For |
| Prudential/PGIM | 347,792 | 0 | 0 | 0 | For |
| TIAA | 340,311 | 0 | 0 | 0 | For |
| Eaton Vance | 320,948 | 0 | 0 | 0 | For |
| Goldman Sachs | 305,967 | 0 | 0 | 0 | For |
| Allspring | 300,550 | 0 | 0 | 0 | For |
| John Hancock | 277,524 | 0 | 0 | 0 | For |
| Principal | 227,704 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 221,954 | 0 | 0 | 0 | For |
Showing the 25 largest of 144 asset managers. All 144 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 100,600,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 10.35% |
| 2 | BlackRock | 7.38% |
| 3 | Fidelity | 1.79% |
| 4 | JPMorgan | 1.45% |
| 5 | T. Rowe Price | 1.34% |
| 6 | State Street | 1.20% |
| 7 | Dodge & Cox | 0.92% |
| 8 | Invesco | 0.87% |
| 9 | JANUS INVESTMENT FUND | 0.80% |
| 10 | Charles Schwab | 0.71% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 5.26% |
| 2 | State Street | 3.59% |
| 3 | Man Group plc | 2.26% |
| 4 | JPMorgan | 1.91% |
| 5 | T. Rowe Price | 1.79% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.67% |
| 7 | Renaissance | 1.44% |
| 8 | Janus Henderson | 1.38% |
| 9 | Dodge & Cox | 1.16% |
| 10 | Rock Springs Capital Management LP | 1.05% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 12,706,230 | 12.63% | Form 13F, quarter ended March 31, 2024 |
| Vanguard Group | 9,706,559 | 9.65% | Form 13F, quarter ended March 31, 2024 |
| JPMorgan Chase | 4,730,152 | 4.70% | Form 13F, quarter ended March 31, 2024 |
| State Street | 3,989,961 | 3.97% | Form 13F, quarter ended March 31, 2024 |
| Renaissance Technologies | 2,251,646 | 2.24% | Form 13F, quarter ended March 31, 2024 |
| Morgan Stanley | 1,826,937 | 1.82% | Form 13F, quarter ended March 31, 2024 |
| T. Rowe Price | 1,820,796 | 1.81% | Form 13F, quarter ended March 31, 2024 |
| Geode Capital | 1,713,714 | 1.70% | Form 13F, quarter ended March 31, 2024 |
| Kevin C. Gorman, Ph.D. | 1,575,454 | 1.57% | Proxy statement (DEF 14A), table as of March 25, 2024 |
| Invesco | 1,136,942 | 1.13% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 100,600,000 shares outstanding, as reported by NEUROCRINE BIOSCIENCES INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At NEUROCRINE BIOSCIENCES INC.'s shareholder meeting held May 22, 2024, in the 2023-2024 proxy season, 567 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 5,159 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Advisory vote on the compensation paid to the Company's named executive officers; — NEUROCRINE BIOSCIENCES INC.'s filing reports the proposal as approved, with 89% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: NEUROCRINE BIOSCIENCES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 23, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NEUROCRINE BIOSCIENCES INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
NEUROCRINE BIOSCIENCES INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “NEUROCRINE BIOSCIENCES (NBIX) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/neurocrine-biosciences-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.